{
  "zip": "2200",
  "sector": "Healthcare",
  "fullTimeEmployees": 114,
  "longBusinessSummary": "Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.",
  "city": "Copenhagen",
  "phone": "45 39 17 82 72",
  "country": "Denmark",
  "companyOfficers": [],
  "website": "http://www.orphazyme.com",
  "maxAge": 1,
  "address1": "Ole MaalOees Vej 3",
  "industry": "Biotechnology",
  "previousClose": 11.3,
  "regularMarketOpen": 13,
  "twoHundredDayAverage": 12.927169,
  "trailingAnnualDividendYield": null,
  "payoutRatio": 0,
  "volume24Hr": null,
  "regularMarketDayHigh": 13,
  "navPrice": null,
  "averageDailyVolume10Day": 250,
  "totalAssets": null,
  "regularMarketPreviousClose": 11.3,
  "fiftyDayAverage": 12.448484,
  "trailingAnnualDividendRate": null,
  "open": 13,
  "averageVolume10days": 250,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": 0.87065,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 13,
  "priceHint": 2,
  "currency": "USD",
  "regularMarketVolume": 500,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 510962400,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": 41,
  "priceToSalesTrailing12Months": null,
  "dayLow": 13,
  "ask": null,
  "ytdReturn": null,
  "askSize": null,
  "volume": 500,
  "fiftyTwoWeekHigh": 18.48,
  "forwardPE": null,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 10.65,
  "bid": null,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": null,
  "dayHigh": 13,
  "exchange": "PNK",
  "shortName": "ORPHAZYME A/S",
  "longName": "Orphazyme A/S",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": false,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "OZYMF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_99715906",
  "uuid": "dde78927-ed24-3923-9882-d1ac93395f64",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": null,
  "beta3Year": null,
  "profitMargins": 0,
  "enterpriseToEbitda": null,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": null,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 34697700,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": null,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1577750400,
  "heldPercentInstitutions": 0.28363,
  "netIncomeToCommon": null,
  "trailingEps": null,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": null,
  "heldPercentInsiders": 0,
  "nextFiscalYearEnd": 1640908800,
  "mostRecentQuarter": 1593475200,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 18859240,
  "enterpriseValue": 305607712,
  "threeYearAverageReturn": null,
  "lastSplitDate": null,
  "lastSplitFactor": null,
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": null,
  "dateShortInterest": null,
  "pegRatio": null,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 13,
  "logo_url": "https://logo.clearbit.com/orphazyme.com"
}